Johnson & Johnson and Legend Biotech are said to have withdrawn an abstract originally planned for next month’s Amer | “At this point, the abstract was withdrawn in alignment with the authors, and we ...
Abstract available on ASH websiteSAN DIEGO and TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a ...
Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established ...
Combination with bispecific T-cell engagers amplifies T-cell recruitment and cytotoxic activity against tumor cells -- Düsseldorf, Germany, ...
Quantum computing is set to redefine data security, AI, and cloud infrastructure. This in-depth research explores how post-quantum cryptography, quantum AI acceleration, and hybrid quantum-cloud ...
T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced multiple presentations on TK-6302 were ...
In this excerpt from the new book 'Speak Data,' the Wharton professor and best-selling author shares his thoughts on how we ...
Shift verification effort from a single, time-consuming flat run to a more efficient, distributed, and scalable process.
Brain activity from more than 1000 people shows a rapid transition from being awake to being asleep, rather than a slow ...
Part one of this three-part series examines the rational for using control technology to reduce process variability ...
The real power of the model context protocol isn’t integration — it’s governance, audibility and safe autonomy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback